- Issuer ticker
-
INKT
- Reported as of
-
01 Dec 2025
- Net transaction value
-
+$13,508
Source evidence
Original filing metadata and source links for verification.
4 source fields
- SEC form
-
4
- Accepted by SEC
-
03 Dec 2025, 16:10:04 UTC
Reporting owner
1 detail
- Reporting owner signature
-
By: /s/ Christine Klaskin, Attorney-in-Fact
Filing notes and source
Key filing fact
Robert Peter Kadlec filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 03 Dec 2025.
Key facts
- This page summarizes Robert Peter Kadlec's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Dec 2025, 16:10.
Change
- Previous filing in this sequence was filed on 11 Sep 2025.
- Current net transaction value: +$13,508.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0002047073
Primary reporting owner
Kadlec Robert Peter
- Relationship
-
Director
- Address
- 149 FIFTH AVENUE, SUITE 500, NEW YORK
- Signature
- By: /s/ Christine Klaskin, Attorney-in-Fact
- Signature date
- 03 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INKT
transaction
Common Stock
Award
- Transaction value
- $13,508
- Shares
- +1,218
- Change %
- +6.8%
- Price
-
$11.09
- Shares after
- 19,126
- Date
- 01 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote